Summary
Pfizer obtains positive results in a phase 3 study treating patients with Transthyretin Cardiomyopathy using Tafamidis.
Patients treated with Tafamidis were able to reduce the risk of mortality by 30% and reduce the rate of cardiovascular-related hospitalization by 32%.
Tafamidis has great potential as it could produce sales between $600 million to $1 billion.
A competing drug from Alnylam recently approved, known as Onpattro, is expected to compete against Tafamidis.
Members of my private investing community, Biotech Analysis Central, can follow this idea, as well as my other top picks with access to my model portfolio. Start your free trial today >>
Recently, Pfizer (PFE) released final results from its phase 3 studytreating patients with a rare heart disease known as Transthyretin cardiomyopathy (TTR-CM). The results were released at a presentation at the ESC Congress 2018. The results were positive, and now the company can explore the potential of obtaining regulatory approval for Tafamidis. I believe that with the results on hand, Pfizer should easily be able to obtain global regulatory approvals for this patient population. For that reason, I think it's a buy.
